Identification of an autoinhibitory domain in the insulin receptor tyrosine kinase
- PMID: 8487750
- DOI: 10.1007/BF00926082
Identification of an autoinhibitory domain in the insulin receptor tyrosine kinase
Abstract
We have tested the hypothesis that activation of the insulin receptor tyrosine kinase is due to autophosphorylation of tyrosines 1146, 1150 and 1151 within a putative autoinhibitory domain. A synthetic peptide corresponding to residues 1134-1162, with tyrosines substituted by alanine or phenylalanine, of the insulin receptor beta subunit was tested for its inhibitory potency and specificity towards the tyrosine kinase activity. This synthetic peptide gave inhibition of the insulin receptor tyrosine kinase autophosphorylation and phosphorylation of the exogenous substrate poly(Glu, Tyr) with an approximate IC50 of 100 microM. Inhibition appeared to be independent of the concentrations of insulin or the substrate poly(Glu, Tyr) but was decreased by increasing concentrations of ATP. This same peptide also inhibited the EGF receptor tyrosine kinase but not a serine/threonine protein kinase. These results are consistent with the hypothesis that this autophosphorylation domain contains an autoinhibitory sequence.
Similar articles
-
Kinase inhibition by a phosphorylated peptide corresponding to the major insulin receptor autophosphorylation domain.Eur J Biochem. 1992 Sep 1;208(2):367-73. doi: 10.1111/j.1432-1033.1992.tb17196.x. Eur J Biochem. 1992. PMID: 1381676
-
Two sequences flanking the major autophosphorylation site of the insulin receptor are essential for tyrosine kinase activation.Biochem J. 1995 Mar 1;306 ( Pt 2)(Pt 2):465-72. doi: 10.1042/bj3060465. Biochem J. 1995. PMID: 7887900 Free PMC article.
-
Replacement of the conserved tyrosine 1210 by phenylalanine in the insulin receptor affects insulin-induced dephosphorylation of focal adhesion kinase but leaves other responses intact.Biochemistry. 1996 Aug 13;35(32):10377-82. doi: 10.1021/bi960350r. Biochemistry. 1996. PMID: 8756693
-
Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.J Pharm Belg. 1997 Mar-Apr;52(2):88-96. J Pharm Belg. 1997. PMID: 9193132 Review.
-
Insulin-receptor tyrosine kinase and glucose transport.Diabetes Care. 1990 Jun;13(6):565-75. doi: 10.2337/diacare.13.6.565. Diabetes Care. 1990. PMID: 2162754 Review.